Logo for Lisata Therapeutics Inc

Lisata Therapeutics Inc Investor Relations Material

Latest events

Logo for Lisata Therapeutics Inc

Q4 2023

Lisata Therapeutics Inc
Logo for Lisata Therapeutics Inc

Q4 2023

29 Feb, 2024
Logo for Lisata Therapeutics Inc

Q3 2023

2 Nov, 2023
Access the full event backlog
Slides, Transcripts, and Reports from 9,000+ public companies

Latest reports from Lisata Therapeutics Inc

Access all reports
Lisata Therapeutics Inc. is a clinical-stage biopharmaceutical company, which focuses on developing and commercializing cellular therapies to reverse disease, promote regeneration and halt disease progression. Its product candidates include HONEDRA, a cell therapy product candidate that is in Phase II clinical trial for the treatment of critical limb ischemia; XOWNA that is in Phase IIb clinical trial for the treatment of coronary microvascular dysfunction; CLBS201, a CD34+ cell therapy for pre-dialysis patients with chronic kidney disease; AB1250-H, an investigational drug product candidate for acute myocardial infarction (AMI) patients who have undergone percutaneous coronary intervention (PCI); and VB6100, an investigational gene therapy product candidate designed to treat demyelinating disorders such as multiple sclerosis